Literature DB >> 22614681

Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer: do they have prognostic impact?

D Vallböhmer1, E Bollschweiler, J Brabender, I Wedemeyer, P P Grimminger, R Metzger, W Schröder, C Gutschow, A H Hölscher, U Drebber.   

Abstract

PURPOSE: Neoadjuvant treatment options have been developed to improve survival of patients with locally advanced rectal cancer. As only patients with a major histopatholocial response benefit from this preoperative therapy, several tumor regression grading systems have been developed. However, currently no accepted comprehensive grading system for clinical use is available. Therefore, we studied the impact of four histological regression grading systems in the neoadjuvant therapy of rectal cancer.
METHODS: In this retrospective study, 85 patients with locally advanced rectal cancer were included. All patients received a neoadjuvant radiochemotherapy followed by surgical resection. The histological regression grading was evaluated using four classification systems: (1) grading system by the Japanese society of colorectal cancer, (2) grading system by Junker-Müller, (3) grading system by Dworak, (4) Cologne grading system. The four classification systems were analyzed for their prognostic impact.
RESULTS: The following significant correlations were detected between the four classification systems and the ypTNM categories: (1) patients with a ypT3/4 category had significantly more often a worse histopathologic response in all four grading systems (p = 0.001); (2) a ypN0 category was significantly correlated with good histopathologic response only in the Cologne grading system; (3) in the Junker-Müller and Dworak grading systems, a ypM0 category was significantly correlated with a good histopathologic response (p = 0.046; p = 0.03). However, none of the used classification systems had a prognostic impact on survival.
CONCLUSIONS: Currently, none of the analyzed histological regression grading systems is effective for clinical use.

Entities:  

Mesh:

Year:  2012        PMID: 22614681     DOI: 10.1007/s00384-012-1487-6

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  15 in total

1.  Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment.

Authors:  K Junker; M Thomas; K Schulmann; F Klinke; U Bosse; K M Müller
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.

Authors:  Christiane Jakob; Torsten Liersch; Wolfdietrich Meyer; Gustavo B Baretton; Wolfgang Schwabe; Peter Häusler; Bettina Kulle; Heinz Becker; Daniela E Aust
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

4.  Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Authors:  Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

5.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

6.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

7.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

8.  Pathological features of rectal cancer after preoperative radiochemotherapy.

Authors:  O Dworak; L Keilholz; A Hoffmann
Journal:  Int J Colorectal Dis       Date:  1997       Impact factor: 2.571

9.  Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?

Authors:  K Horisberger; R D Hofheinz; P Palma; A K Volkert; S Rothenhoefer; F Wenz; A Hochhaus; S Post; F Willeke
Journal:  Int J Colorectal Dis       Date:  2007-12-11       Impact factor: 2.571

10.  Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer.

Authors:  Shingo Tsujinaka; Yutaka J Kawamura; Fumio Konishi; Hiroyuki Aihara; Takafumi Maeda; Ken Mizokami
Journal:  Int J Colorectal Dis       Date:  2007-08-18       Impact factor: 2.571

View more
  4 in total

1.  Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma.

Authors:  M J Fernández-Aceñero; M Granja; J Sastre; B García-Paredes; L Estrada
Journal:  Virchows Arch       Date:  2016-01-11       Impact factor: 4.064

2.  Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters.

Authors:  Andreas M Hötker; Lisa Tarlinton; Yousef Mazaheri; Kaitlin M Woo; Mithat Gönen; Leonard B Saltz; Karyn A Goodman; Julio Garcia-Aguilar; Marc J Gollub
Journal:  Eur Radiol       Date:  2016-03-05       Impact factor: 5.315

Review 3.  Pathologic processing of the total mesorectal excision.

Authors:  Molly Campa-Thompson; Robert Weir; Natalie Calcetera; Philip Quirke; Susanne Carmack
Journal:  Clin Colon Rectal Surg       Date:  2015-03

Review 4.  Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales.

Authors:  Muhammed R S Siddiqui; Jemma Bhoday; Nicholas J Battersby; Manish Chand; Nicholas P West; Al-Mutaz Abulafi; Paris P Tekkis; Gina Brown
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.